{"id":"2940c5adad49","type":"article","url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","title":"3-jaarsresultaten van bioresorbeerbare scaffolds: ABSORB III-trial","title_en":"3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2017.10.010","source_url":"https://doi.org/10.1016/j.jacc.2017.10.010","authors":["Dean J Kereiakes","Stephen G Ellis","Christopher Metzger","Ronald P Caputo","David G Rizik","Paul S Teirstein","Marc R Litt","Annapoorna Kini","Ameer Kabour","Steven O Marx","Jeffrey J Popma","Robert McGreevy","Zhen Zhang","Charles Simonton","Gregg W Stone"],"significance":7,"published":"2017-12-12","source_date":"2017-12-12","image":"","kennis":[],"congress":"","summary_en":"The ABSORB III 3-year results showed increasing rates of scaffold thrombosis with the bioresorbable vascular scaffold compared with the Xience metallic stent. This late safety signal contributed to the commercial withdrawal of the Absorb device.","created":"2026-07-03T10:27:03Z","updated":"2026-07-03T13:26:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"3-jaarsresultaten van de ABSORB III-trial die toenemende scaffoldtrombose toonden. Droeg bij aan de beslissing om Absorb van de markt te halen.","abstract_original":"BACKGROUND: The Absorb everolimus-eluting poly-L-lactic acid-based bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support functions similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximately 3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI], or ischemia-driven target lesion revascularization) at 1 year in 2,008 patients with coronary artery disease randomized to BVS versus cobalt-chromium everolimus-eluting stents (EES). OBJECTIVES: This study sought to assess clinical outcomes through 3 years following BVS implantation. METHODS: Clinical outcomes from the ABSORB III trial were analyzed by randomized treatment assignment cumulative through 3 years, and between 1 and 3 years. RESULTS: The primary composite endpoint of target lesion failure through 3 years occurred in 13.4% of BVS patients and 10.4% of EES patients (p = 0.06), and between 1 and 3 years in 7.0% versus 6.0% of patients, respectively (p = 0.39). TVMI through 3 years was increased with BVS (8.6% vs. 5.9%; p = 0.03), as was device thrombosis (2.3% vs. 0.7%; p = 0.01). In BVS-assigned patients, treatment of very small vessels (those with quantitatively determined reference vessel diameter <2.25 mm) was an independent predictor of 3-year TLF and scaffold thrombosis. CONCLUSIONS: In the ABSORB III trial, 3-year adverse event rates were higher with BVS than EES, particularly TVMI and device thrombosis. Longer-term clinical follow-up is required to determine whether bioresorption of the polymeric scaffold will influence patient prognosis. (ABSORB III Randomized Controlled Trial [RCT] [ABSORB-III]; NCT01751906)."}